New data for PD-1 inhibitors sponsored by Merck & Co. Inc. and Bristol-Myers Squibb Co. suggest more changes ahead soon for the standard of care in melanoma, a field that has already just been drastically altered by the introduction of checkpoint inhibition.
Both companies presented data for their drugs as a first-line treatment for advanced melanoma at the American Association for Cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?